A preclinical study of allogeneic <scp>CD19</scp> chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignanciesDan Wang, Liming Yang, Liuyang Wang et al.|Clinical & Translational Immunology|2024Cited by 2
Supplemental Legend from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0
Supplementary Table S1 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0
Figure S4 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0
Figure S2 from Use of <i>Ex</i> <i>Vivo</i> Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for <i>HER2</i> Mutant Non–Small Cell Lung CancerElena P. Ivanova, Pasi A. Jänne, Mari Kuraguchi et al.|Unknown|2023Cited by 0